Background. The drug-eluting beads transarterial chemoembolization (DEB-TACE) has already been used in hepatic malignancies. We aim to evaluate the efficacy and safety of DEB-TACE in treating primary or secondary liver cancer. Methods. We retrospectively evaluated 59 patients with hepatic malignancies, including 41 patients with primary liver cancer and 18 patients with secondary liver cancer, between September 2016 and February 2019. All patients were treated with DEB-TACE. Objective response rate (ORR) and disease control rate (DCR) were evaluated by mRECIST. The pain was assessed using a numerical rating scale (NRS) where 0 represented no pain, and a score of ten was unbearable. Adverse reactions were assessed according to Common Terminology Criteria for Adverse Events 4.0 (CTCAE4.0). Results. In the subgroup of primary liver cancer, 3 patients (7.32%) got complete response, 13 patients (31.71%) got partial response, 21 patients (51.22%) experienced stable disease, and 4 patients (9.76%) suffered progressive disease; ORR was 39.02% and DCR was 90.24%. In the subgroup of secondary liver cancer, 0 patients (0%) got complete response, 6 patients (33.33%) got partial response, 11 patients (61.11%) experienced stable disease, and 1 patient (5.56%) suffered progressive disease; ORR was 33.33% and DCR was 94.44%. We did not find any difference when comparing the efficacy between primary and secondary liver cancer (). The one-year survival rate was 70.73% for primary liver cancer and 61.11% for secondary liver cancer. There was no significant difference between the two groups (). For the patients with CR or PR, no factor could predict the efficacy of DEB-TACE. The most common treatment-related adverse reactions were short-term liver function disorders. The symptoms included fever (20.34%), abdomen pain (16.95%), and vomiting (5.08%), all patients with adverse reactions got remission after treatment. Conclusions. DEB-TACE has a promising effect in the treatment of primary or secondary liver cancer. The treatment-related adverse reactions are tolerable.

中文翻译：

---

药物洗脱微珠 TACE 治疗原发性或继发性肝癌的疗效和安全性

背景。药物洗脱珠经动脉化疗栓塞术 (DEB-TACE) 已用于肝脏恶性肿瘤。我们旨在评估 DEB-TACE 治疗原发性或继发性肝癌的有效性和安全性。方法。我们回顾性评估了 2016 年 9 月至 2019 年 2 月期间的 59 例肝脏恶性肿瘤患者，包括 41 例原发性肝癌患者和 18 例继发性肝癌患者。所有患者均接受了 DEB-TACE 治疗。采用mRECIST评估客观缓解率（ORR）和疾病控制率（DCR）。使用数字评定量表 (NRS) 评估疼痛，​​其中 0 表示没有疼痛，10 分表示难以忍受。根据不良事件通用术语标准 4.0 (CTCAE4.0) 评估不良反应。结果。原发性肝癌亚组完全缓解3例（7.32%），部分缓解13例（31.71%），病情稳定21例（51.22%），疾病进展4例（9.76%）；ORR 为 39.02%，DCR 为 90.24%。继发性肝癌亚组完全缓解0例（0%），部分缓解6例（33.33%），病情稳定11例（61.11%），进展1例（5.56%）；ORR 为 33.33%，DCR 为 94.44%。在比较原发性和继发性肝癌的疗效时，我们没有发现任何差异（). 原发性肝癌一年生存率为70.73%，继发性肝癌为61.11%。两组间无显着差异（). 对于 CR 或 PR 的患者，没有任何因素可以预测 DEB-TACE 的疗效。最常见的治疗相关不良反应是短期肝功能障碍。症状包括发热（20.34%）、腹痛（16.95%）、呕吐（5.08%），所有不良反应患者经治疗后均得到缓解。结论。DEB-TACE 在治疗原发性或继发性肝癌方面具有良好的疗效。治疗相关的不良反应是可以忍受的。